ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
1.050
+0.030 (2.94%)
Sep 4, 2025, 11:02 AM - Market open
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
80
Market Cap
56.23M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 1.18M | -3.61M | -75.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ALXO News
- 5 days ago - ALX Oncology to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 16 days ago - ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors - GlobeNewsWire
- 22 days ago - ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 3 months ago - ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewsWire
- 3 months ago - ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - GlobeNewsWire
- 4 months ago - ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - GlobeNewsWire